Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Nordic Nanovector ASA. (1/8/16). "Press Release: Nordic Nanovector to Present at the 8th Annual Biotech Showcase Conference in San Francisco". Oslo.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation Nordic Nanovector ASA (OSE: NANO)
  Group Nordic Nanovector (Group)
  Organisation 2 Citigate Dewe Rogerson Ltd.
  Group Huntsworth (Group)
Products Product Biotech Showcase 2016 San Francisco
  Product 2 Betalutin®
Index terms Index term Nordic Nanovector–Informa: partnering conference, 201601 supply service Nordic Nanovector ASA presents at Biotech Showcase 2016
  Index term 2 Nordic Nanovector–Huntsworth: public relations, 201601 service existent media relations by Citigate Dewe Rogerson
Persons Person Costa, Luigi (Nordic Nanovector 201409– CEO before Onyx Pharmaceuticals + Amgen)
  Person 2 Kvåle, Tone (Nordic Nanovector 201409 CFO)

Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, announces that the Company will present a corporate overview at the 8th Annual Biotech Showcase Conference in San Francisco on Wednesday, 13 January 2016, at 9:30am PST in Room Mission II (4th Floor) at the Parc 55 San Francisco.

The presentation will be available on the Company’s website following the event.

Nordic Nanovector will also attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, 11-14 January 2016 and the Trout Management Access Event, which runs in parallel.


For further information, please contact:

Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76

Victoria Igumnova (Trout International LLC)
Cell: +44 750 763 1280

International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.

Further information about the Company can be found at

Press Release 1/2016.

Record changed: 2017-07-02


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Nordic Nanovector (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

» top